{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:58:03Z","timestamp":1775473083934,"version":"3.50.1"},"reference-count":29,"publisher":"Medical Association of Zenica-Doboj","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinski Glasnik"],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"&lt;p&gt;&lt;strong&gt;Aim &lt;br \/&gt;&lt;\/strong&gt;To investigate the benefit of high-dose lipophilic statin therapy on cardiac remodelling, function and progression of heart failure (HF) in patients with ischemic heart disease.&lt;br \/&gt;&lt;strong&gt;Methods &lt;br \/&gt;&lt;\/strong&gt;A total of 80 patients with ischemic HF diagnosis were followed during 6 months, and they were divided in two groups.&lt;br \/&gt;First group (n=40) was treated by high-dose lipophilic statin therapy (atorvastatin 40 mg) and conventional therapy for HF, while the second group (n=40) had no atorvastatin in the therapy.&lt;br \/&gt;&lt;strong&gt;Results&lt;\/strong&gt; &lt;br \/&gt;In the beginning of study, from all of the observed parameters, only the ratio of flow rates in early and late diastole (E\/A&lt;br \/&gt;ratio) differed between the test groups (p=0.007). After six months, a statistically significant increase in left ventricular end-diastolic diameter (LVIDD) in patients who had not been treated with atorvastatin was found. In the patients treated with atorvastatin, there was a significant reduction in basal right ventricle diameter in diastole and systole (p&amp;lt;0.001 and p&amp;lt;0.001, respectively), and in tricuspid annular plane systolic excursion (TAPSE) (p&amp;lt;0.001); there was a reduction in LVIDD (p&amp;lt;0.001), and an increase of ejection fraction of the left ventricle according to Teicholtz and Simpson&lt;br \/&gt;(p&amp;lt;0.001 and p&amp;lt;0.001, respectively). Also, there was an increase of deceleration time of early diastolic velocity (DTE) (p&amp;lt;0.05) and a decrease of isovolumic relaxation time (IVRT) (p&amp;lt;0.001).&lt;br \/&gt;&lt;strong&gt;Conclusion&lt;\/strong&gt; &lt;br \/&gt;The reduction in the right and left ventricle diameters was noted after the six-month atorvastatin therapy. Atorvastatin in&lt;br \/&gt;the therapy resulted in increased EFLV and better systolic function and should be a part of a therapeutic modality of HF.&lt;\/p&gt;<\/jats:p>","DOI":"10.17392\/1388-21","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:28:16Z","timestamp":1713695296000},"page":"357-361","source":"Crossref","is-referenced-by-count":0,"title":["Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF)"],"prefix":"10.17392","volume":"18","author":[{"given":"Faris","family":"Zvizdi\u0107","sequence":"first","affiliation":[{"name":"Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Centre, University of Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"],"department":["Department of Cardiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-262X","authenticated-orcid":false,"given":"Edin","family":"Begi\u0107","sequence":"additional","affiliation":[{"name":"General Hospital \"Prim. Dr. Abdulah Naka\u0161\"","place":["Sarajevo,Bosnia and Herzegovina"],"department":["Department of Cardiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirza","family":"Dili\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160ekib","family":"Sokolovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Centre, University of Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"],"department":["Department of Cardiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Lepara","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"],"department":["Department of Physiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"49509","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref1","first-page":"11","article-title":"Update on heart failure management and future directions","author":"HChoiH","year":"2019","unstructured":"Choi HM, Park MS, Youn JC. Update on heart fa-\nilure management and future directions. Korean J \nIntern Med 2019; 3:11-43.","journal-title":"Korean J Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: pros and cons","author":"IPinal-FernandezI","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen \nAL. Statins: pros and cons. Med Clin (Barc) 2018; \n150:398-402.","journal-title":"Med Clin (Barc)"},{"key":"ref3","first-page":"873","article-title":"Pleiotropic effects of statin in therapy in heart failure: a review","author":"MCorrealeM","year":"2014","unstructured":"Correale M, Abruzzese S, Greco CA, Concilio M, \nBiase MD, Brunetti ND. Pleiotropic effects of sta-\ntin in therapy in heart failure: a review. Curr Vasc \nPharm 2014; 12:873-84.","journal-title":"Curr Vasc Pharm"},{"key":"ref4","first-page":"406","article-title":"Beyond lipid lowering: pleiotropic effects of statins in heart failure","author":"CSwenneC","year":"2013","unstructured":"Swenne CA. Beyond lipid lowering: pleiotropic \neffects of statins in heart failure. Neth Heart J 2013; \n21:406-7.","journal-title":"Neth Heart J"},{"key":"ref5","article-title":"Statins and inflammation in cardiovascular disease","author":"GVogiatziG","year":"2017","unstructured":"Vogiatzi G, Oikonomou E, Siasos G, Tsalamandris \nS, Briasoulis A, Androulakis E, Latsios G, Papai-\noannou S, Tsioufis K, Tousoulis D. Statins and in-\nflammation in cardiovascular disease. Curr Pharm \nDes 2017.","journal-title":"Curr Pharm Des"},{"key":"ref6","first-page":"1590","article-title":"Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure","author":"LWangL","year":"2013","unstructured":"Wang L, Shi J, Zhang Y. Influences of simvastatin \non vascular endothelial function of patients with \ncoronary heart disease complicated with congesti-\nve heart failure. Eur Rev Med Pharmacol Sci 2013; \n17:1590-3.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2014.12.014","article-title":"Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients","author":"EOikonomouE","year":"2015","unstructured":"Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, \nMourouzis K, Chrysohoou C, Zisimos K, Mazaris \nS, Tourikis P, Athanasiou D, Stefanadis C, Papava-\nssiliou AG, Tousoulis D. Atorvastatin treatment im-\nproves endothelial function through endothelial pro-\ngenitor cells mobilization in ischemic heart failure \npatients. Atherosclerosis 2015; 238:159-64.","journal-title":"Atherosclerosis"},{"key":"ref8","first-page":"222","article-title":"Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease","author":"JLiJ","year":"2010","unstructured":"Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. \nComparison of effects of simvastatin versus atorva-\nstatin on oxidative stress in patients with coronary \nheart disease. Clin Cardiol 2010; 33:222-7.","journal-title":"Clin Cardiol"},{"key":"ref9","first-page":"41","article-title":"Statins and oxidative stress in chronic heart failure","author":"SCostaS","year":"2016","unstructured":"Costa S, Reina-Couto M, Albino-Teixeira A, Sousa \nT. Statins and oxidative stress in chronic heart failu-\nre. Rev Port Cardiol 2016; 35:41-57.","journal-title":"Rev Port Cardiol"},{"key":"ref10","first-page":"30","article-title":"A Review of the role of statins in heart failure treatment","author":"MNiaziM","year":"2020","unstructured":"Niazi M, Galehdar N, Jamshidi M, Mohammadi R, \nMoayyedkazemi A. A Review of the role of statins in \nheart failure treatment. Curr Clin Pharmacol 2020; \n15:30-7.","journal-title":"Curr Clin Pharmacol"},{"key":"ref11","first-page":"48","article-title":"Discovering and identifying New York heart association classification from electronic health records","author":"RZhangR","year":"2018","unstructured":"Zhang R, Ma S, Shanahan L, Munroe J, Horn S, \nSpeedie S. Discovering and identifying New York \nheart association classification from electronic he-\nalth records. BMC Med Inform Decis Mak 2018; \n18:48.","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref12","first-page":"1599","article-title":"Oneyear outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)","author":"HSelkerH","year":"2014","unstructured":"Selker HP, Udelson JE, Massaro JM, Ruthazer R, \nD'Agostino RB, Griffith JL, Sheehan PR, Desvigne-\nNickens P, Rosenberg Y, Tian X, Vickery EM, Atkins \nJM, Aufderheide TP, Sayah AJ, Pirrallo RG, Levy \nMK, Richards ME, Braude DA, Doyle DD, Frascone \nRJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter \nGP, Wayne MA, Woolard RH, Beshansky JR. One-\nyear outcomes of out-of-hospital administration of \nintravenous glucose, insulin, and potassium (GIK) \nin patients with suspected acute coronary syndromes \n(from the IMMEDIATE [Immediate Myocardial \nMetabolic Enhancement During Initial Assessment \nand Treatment in Emergency Care] Trial). Am J Car-\ndiol 2014; 113:1599-605.","journal-title":"Am J Cardiol"},{"key":"ref13","first-page":"53","article-title":"High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials","author":"ABenjoA","year":"2015","unstructured":"Benjo AM, El-Hayek GE, Messerli F, DiNicolan-\ntonio JJ, Hong MK, Aziz EF, Herzog E, Tamis-Ho-\nlland J. High dose statin loading prior to percutaneo-\nus coronary intervention decreases cardiovascular \nevents: a meta-analysis of randomized controlled \ntrials. Catheter Cardiovasc Interv 2015; 85:53-60.","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref14","first-page":"2149","article-title":"Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?","author":"CKimC","year":"2018","unstructured":"Kim C, Choi D. Timing of high intensity statin for \nacute coronary syndrome: how earlier initiation ma-\nkes better? J Thorac Dis 2018; 10:S2149-52.","journal-title":"J Thorac Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","author":"ENavareseE","year":"2014","unstructured":"Navarese EP, Kowalewski M, Andreotti F, van Wely \nM, Camaro C, Kolodziejczak M, Gorny B, Wirianta \nJ, Kubica J, Kelm M, de Boer MJ, Suryapranata H. \nMeta-analysis of time-related benefits of statin the-\nrapy in patients with acute coronary syndrome un-\ndergoing percutaneous coronary intervention. Am J \nCardiol 2014; 113:1753-64.","journal-title":"Am J Cardiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes","author":"CCannonC","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, \nRouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer \nMA, Skene AM; Pravastatin or Atorvastatin Eva-\nluation and Infection Therapy-Thrombolysis in \nMyocardial Infarction 22 Investigators. Intensive \nversus moderate lipid lowering with statins after \nacute coronary syndromes. N Engl J Med 2004; \n350:1495-504.","journal-title":"N Engl J Med"},{"key":"ref17","first-page":"1622","article-title":"Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies","author":"GPattiG","year":"2011","unstructured":"Patti G, Cannon CP, Murphy SA, Mega S, Pasce-\nri V, Briguori C, Colombo A, Yun KH, Jeong MH, \nKim JS, Choi D, Bozbas H, Kinoshita M, Fukuda \nK, Jia XW, Hara H, Cay S, Di Sciascio G. Clinical \nbenefit of statin pretreatment in patients undergoing \npercutaneous coronary intervention: a collaborative \npatient-level meta-analysis of 13 randomized studi-\nes. Circulation 2011; 123:1622-32.","journal-title":"Circulation"},{"key":"ref18","first-page":"1711","article-title":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACLE study: a randomized controlled trial","author":"GSchwartzG","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, \nOliver MF, Waters D, Zeiher A, Chaitman BR, Le-\nslie S, Stern T; Myocardial Ischemia Reduction with \nAggressive Cholesterol Lowering (MIRACL) Study \nInvestigators. Effects of atorvastatin on early recu-\nrrent ischemic events in acute coronary syndromes: \nThe MIRACLE study: a randomized controlled tri-\nal. JAMA 2001; 285:1711-8.","journal-title":"JAMA"},{"issue":"2","key":"ref19","article-title":"Pravastatin in Acute Coronary Treatment (PACT) Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial","author":"PThompsonP","year":"2004","unstructured":"Thompson PL, Meredith I, Amerena J, Campbell \nTJ, Sloman JG, Harris PJ; Pravastatin in Acute Co-\nronary Treatment (PACT) Investigators. Effect of \npravastatin compared with placebo initiated within \n24 hours of onset of acute myocardial infarction or \nunstable angina: the Pravastatin in Acute Coronary \nTreatment (PACT) trial. Am Heart J 2004; 148:e2.","journal-title":"Am Heart J"},{"key":"ref20","first-page":"177","article-title":"Lipophilic statin versus rosuvastatin (hydrophilic) treatment for heart failure: a meta-analysis and adjusted indirect comparison of randomised trials","author":"KBonsuK","year":"2016","unstructured":"Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic \nstatin versus rosuvastatin (hydrophilic) treatment for \nheart failure: a meta-analysis and adjusted indirect \ncomparison of randomised trials. Cardiovasc Drugs \nTher 2016; 30:177-88.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref21","first-page":"117","article-title":"pharmacokinetic and pharmacodynamic properties of statins: an update","author":"MSchachterM","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and phar-\nmacodynamic properties of statins: an update. Fun-\ndam Clin Pharmacol 2005; 19:117-25.","journal-title":"Fundam Clin Pharmacol"},{"key":"ref22","first-page":"249","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","author":"JKjekshusJ","year":"1997","unstructured":"Kjekshus J, Pedersen TR, Olsson AG, Faergeman \nO, Py\u00f6r\u00e4l\u00e4 K. The effects of simvastatin on the inci-\ndence of heart failure in patients with coronary heart \ndisease. J Card Fail 1997; 3:249-54.","journal-title":"J Card Fail"},{"key":"ref23","first-page":"117","article-title":"Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials","author":"LZhangL","year":"2011","unstructured":"Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J. \nEffects of statin treatment on cardiac function in \npatients with chronic heart failure: a meta-analysis \nof randomized controlled trials. Clin Cardiol 2011; \n34:117-23.","journal-title":"Clin Cardiol"},{"key":"ref24","first-page":"970","article-title":"Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials","author":"GLiuG","year":"2014","unstructured":"Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH. \nEffects of lipophilic statins for heart failure: a me-\nta-analysis of 13 randomised controlled trials. Heart \nLung Circ 2014; 23:970-7.","journal-title":"Heart Lung Circ"},{"key":"ref25","first-page":"140","article-title":"Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure","author":"BVrtovecB","year":"2008","unstructured":"Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc \nV, Schlegel TT, Radovancevic B. Atorvastatin the-\nrapy may reduce the incidence of sudden cardiac de-\nath in patients with advanced chronic heart failure. J \nCard Fail 2008; 14:140-4.","journal-title":"J Card Fail"},{"key":"ref26","first-page":"1128","article-title":"Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the echocardiographic heart of Rengland 350 screening study (ECHOES)","author":"FHobbsF","year":"2007","unstructured":"Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare \nR. Prognosis of all-cause heart failure and bor-\nderline left ventricular systolic dysfunction: 5 year \nmortality follow-up of the echocardiographic heart \nof Rengland 350 screening study (ECHOES). Eur \nHeart J 2007; 28:1128-34.","journal-title":"Eur Heart J"},{"key":"ref27","first-page":"657","article-title":"Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial","author":"CWuC","year":"2017","unstructured":"Wu CK, Yeh CF, Chiang JY, Lin TT, Wu YF, Chiang \nCK, Kao TW, Hung KY, Huang JW. Effects of ator-\nvastatin treatment on left ventricular diastolic func-\ntion in peritoneal dialysis patients-The ALEVENT \nclinical trial. J Clin Lipidol 2017; 11:657-66.","journal-title":"J Clin Lipidol"},{"key":"ref28","first-page":"332","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","author":"SSolaS","year":"2006","unstructured":"Sola S, Mir MQS, Khan BV, Lerakis S, Tandon N. \nAtorvastatin improves left ventricular systolic func-\ntion and serum markers of inflammation in nonische-\nmic heart failure. J Am Coll Cardiol 2006; 47:332-7.","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis","author":"ABielecka-DabrowaA","year":"2019","unstructured":"Bielecka-Dabrowa A, Byty\u00e7i I, Von Haehling S, An-\nker S, Jozwiak J, Rysz J, Hernandez AV, Bajraktari \nG, Mikhailidis DP, Banach M. Association of statin \nuse and clinical outcomes in heart failure patients: a \nsystematic review and meta-analysis. Lipids Health \nDis 2019; 18:188.","journal-title":"Lipids Health Dis"}],"container-title":["Medicinski Glasnik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medicinskiglasnik.ba\/article\/38\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicinskiglasnik.ba\/article\/38\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:44:34Z","timestamp":1775468674000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicinskiglasnik.ba\/article\/id\/300\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.17392\/1388-21","archive":["Internet Archive"],"relation":{},"ISSN":["1840-0132","1840-0132"],"issn-type":[{"value":"1840-0132","type":"electronic"},{"value":"1840-0132","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}